Antiulcer Activity after Oral Administration of the Wormwood Ethanol Extract on Lesions due to Leishmania major Parasites in BALB/C Mice by Mohammad Djaefar Moemenbellah-Fard,	Qasem Asgari,	Soliman Mohammadi-Samani, Kourosh Azizi, Fatemeh Shahidi-Hakak
AbstractHerbal extracts were used to investigate the in vivo efficacy of Artemisia absinthium on the treatment of cutaneous leishmaniasis in susceptible mice. A total of 40 BALB/c mice were subjected to assays. In each, 3-5×103 amastigotes of standard Leishmania major strain were inoculated subcutaneously into the tail base of mice. Groups of mice were assigned 
as: I-negative control, II-positive control, III-Glucantime®, IV-ointment twice a day, V-ointment with oral medicine, VI-oral 
medicine on parasite injection, VII-oral medicine once ulcer develops, and VIII-ointment-based crème on ulcer. The gold 
standard of clinical infection control was based on ulcer size measurement using a Vernier scale weekly during 4 weeks 
Post-Ulcer Development (PUD). The mean ulcer sizes in different groups were compared using the post hoc Dunnett’s 3 
statistical analyses. There was a significant difference between the two groups of ointment with medicine (V) and medicine 
on parasite inoculation (VI) (P ≤ 0.027). Antiulcer activity and healing was noted after oral treatment with aqueous extract 
on parasite injection. There was a significant difference between data from positive control group and local ointment with 
oral medicine (P ≤ 0.045) indicating that ointment use facilitated ulcer growth. There was also a significant difference 
between data from Glucantime® use and ointment with medicine group (P ≤ 0.039) which showed the deteriorating effect 
of oil-based ointment use. The oral administration of extract had an effect similar to Glucantime® use and led to the repair of ulcer. A. absinthium extract as oral feeder appeared to cause modulation of host responses, ulcer size reduction and tissue repair.
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1. Introduction
Cutaneous Leishmaniases (CL), as ulcerative skin lesions 
caused by the flagellate protozoan parasites in the genus 
Leishmania (Kinetoplastida: Trypanosomatidae), rep-
resent widespread neglected zoonotic and public health 
diseases being endemic in most developing countries 
of Africa, Latin America, and Asia including Iran42. CL 
is the second most important vector-borne protozoan 
disease in Iran, after malaria28. The national incidence 
rate of CL disease has risen from 0.002 to 1.337 over 
the first decade of this century22. CL transmission is, 
however, anthroponotic or zoonotic based on whether 
the main reservoir host is human or other mammals34. 
Among 15 well-defined Leishmania species known to 
cause parasitic infection in humans, 13 have a zoonotic 
natural history16. Most transmission cycles of Iranian CL 
cases are zoonoses27. The parasite is transmitted by the 
female blood-sucking phlebotomine sand flies (Diptera: 
Psychodidae) often feeding on rodent reservoir hosts 
prior to biting humans2,3.
Chemotherapy with pentavalent antimonial drugs, 
like meglumine antimoniate (Glucantime®), is still the 
mainstay activity in endemic areas of Iran17. CL treat-
ment is often impeded by the development of drug 
resistance11, side effects like cardiac and renal toxicities, 
variable efficacy, necessity to endure long courses of 
parenteral administration, the absence of an effective vac-
cine, as well as the formidable task of developing a simple, 
cheap, sustainable and swift drug-evaluating system glob-
ally effective on the different Leishmania species/strains 
infecting humans; though this being too optimistic20. 
Attempts to identify alternative search strategies are thus 
conspicuously essential25. About 80% of the world’s inhab-
itants depend on folk medicines for their healthcare9. 
Traditional treatment of CL includes the administration 
of natural products from medicinal herbs such as worm-
wood, Artemisia, in some parts of the world6,35.
Medicinal herbs are normally rich sources of various 
types of bioactive organic compounds. The medicinal 
plant genus Artemisia is one of the largest and most wide-
spread members of the daisy family in the world which 
includes about 500 species growing mostly in temperate 
regions of Asia, Europe and North America5. One of these 
botanicals, known commonly as the absinthe worm-
wood Artemisia absinthium L. (Asteraceae/Compositae), 
is an aromatic perennial herb with silvery-green foli-
age growing naturally native on dry open slopes in Fars 
province, south Iran. They are characterized to have mul-
tiple diverse effects. Their efficacy could be due to the 
composition and biochemical effects of various volatile 
Essential Oils (EOs) which are reported to have antifun-
gal40, antimicrobial12,31, and antiparasitic1,39 effects against 
Leishmania species. Additionally, certain EOs from A. 
absinthium has been reported to bear acaricidal8, insec-
ticidal23, and repellent activities against fleas, flies, gnats, 
and ticks21.
Much of the studies on the detection of natural 
medicinal products with anti-Leishmania activity have 
been performed using the promastigote (flagellate) or 
sand fly stage of the parasite as it is more amenable to 
maintain under in vitro conditions. However, since the 
extracellular promastigote is not the pathogenic form of 
the parasite in vertebrate hosts, assays carried out with 
promastigotes have solely an indicative value of the 
likely anti-Leishmania activity of the herbal extract or 
its metabolite tested. An initial evaluation using promas-
tigotes have thus to be complemented with an assay on 
intracellular amastigotes within parasitophorous vacu-
oles of vertebrate host’s macrophages7. Consequently, a 
recent study was conducted on the in vitro activities of 
A. absinthium on Leishmania major parasites, using a 
series of synchronous cell sensitivity and flow cytometry 
assays4. A growth inhibitory concentration (IC50) and a 
lethal concentration (LC50) of 16.6 and 101µgml
-1 were 
thus recorded, respectively. In the present study, the 
main aim was to unravel the in vivo antiulcer efficacy 
of A. absinthium medicinal herb ethanol extract on the 
treatment of CL lesions caused by L. major parasites in 
susceptible BALB/c mice. To the best of authors’ knowl-
edge, there appear to have been no previous reports on 
the in vivo effects of absinthe wormwood against lesions 
induced by L. major amastigotes parasites within the 
scope of this investigation.
2. Materials and Methods
Plant identification, preparation, and isolation of its 
extracts as well as parasite culture were previously 
described4. The hydro alcoholic extract obtained from 
A. absinthium was then delivered to pharmaceutical 
Department of the School of Pharmacy for the preparation 
of 90% ointment. The creme based formulation comprised 
18 g liquid paraffin, 7 g Vaseline, 5 g Cetostearyl alcohol, 
3 g Cetomacrogol, 0.5 g Carbomer in 70 g distilled water, 
and 5 ml of one normal sodium hydroxide (NaOH).
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major-infected mice were removed after detachment. 
The serosal fluids from below lesion clots were taken up 
and transferred to physiological sera. A suspension of 
parasites, physiological serum and antibiotics (100 µg/
ml streptomycin, and penicillin 100 U/ml) were thus 
prepared. Using a Neobar Chamber slide on an inverted 
compound microscope, parasite counts were examined 
by taking samples from this suspension. In addition, a 
drop of amastigote parasites suspension was poured onto 
a microscope slide, air-dried, methanol-fixed, and stained 
in Giemsa for direct observation. All susceptible BALB/c 
mice, except those in the first group, were subcutaneously 
inoculated at their tail base with equal volumes of 3-5x103 
amastigotes of standard Iranian L. major parasite strain 
MRHO/IR/75/ER. After three weeks of parasite inocula-
tion, a raised nodule was felt at the site of entry which 
resulted in an open ulcer.
2.3 Treatments and Measurements
The first naïve group was solely treated with oral medi-
cine. Those groups which were treated with oral medicine 
received 1.4 g/kg drug daily. The second group (positive 
control) did not receive any treatment as it was solely 
inoculated with parasites. The groups of I, II, IV, V, and 
VIII were followed up and except group II received treat-
ments for 4 weeks. The groups of VI and VII were treated 
for 5 weeks. The mice in group III received daily intra-
muscular (i.m.) inoculation of 0.6 mg/kg Glucantime® for 
a period of 21 days (Figure 1).
2.1 Laboratory Animals
All experimental animals were susceptible BALB/c male 
mice between 4-6 weeks old and weighing 18-24 g which 
were supplied from the Institute of Pasteur at the Iranian 
capital city of Tehran. These mice were grouped into eight 
batches of five mice as follows:
• Group I: Naïve uninfected mice but oral treatment 
with drug (negative control).
• Group II: Untreated but infected with amastigote par-
asites (positive control).
• Group III: Intramuscular Glucantime® injection 3 
weeks Post-Ulcer Development (PUD).
• Group IV: Local ointment twice (A.M. and P.M.) a day 
PUD.
• Group V: Local ointment twice daily with oral medi-
cine PUD.
• Group VI: Aqueous oral medicine upon parasite inoc-
ulation.
• Group VII: Aqueous oral medicine once ulcer appears.
• Group VIII: Local application of ointment-based 
crème once ulcer appears.
2.2  Parasite Inoculation into Susceptible 
BALB/c Mice
Experimental infections of susceptible BALB/c mice 
were performed using Leishmania major parasitic amas-
tigotes. To inoculate parasites, the lesion clots from 5 L. 
Figure 1. A BALB/c mouse is being injected with Glucantime® drug into its calf muscle.
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Prior to treatments, the ulcer areas on mice in each 
experimental group were recorded following measure-
ments. They were also re-measured during the course of 
treatments once a week and the data on ulcer areas were 
noted. The length and width of each ulcer were directly 
measured with a Collis Vernier caliper scale, and its area 
was calculated using the formula of: S = a/2.b/2.π; where 
‘a’ variable was the length and ‘b’ was the width of each 
ulcer.
2.4 Data Analysis
In order to compare the mean size of ulcers between 
different mice groups, the statistical test of Analysis of 
Variance (ANOVA) was used. Data analysis by ANOVA 
was significant, but the presumption of equal variances 
was not established. Therefore, the post hoc Dunnett’s T3 
statistical analyses were used to determine the efficacy of 
different treatment regimes. In addition, P-values of 0.05 
or less (or a confidence interval of 95%) were considered 
significant. Data analysis was done using SPSS software 
version 16.
3. Results
The data analysis revealed that there was a significant 
difference between ulcer sizes in the two groups of V 
and VI (P ≤ 0.027); that is oral medicine upon parasite 
inoculation and ointment twice daily with oral medicine 
post-ulcer development; PUD (Table 1). This ameliora-
tive response of lesion growth retardation was similar 
to that of the oral administration of Glucantime® PUD 
which culminated in lesion repair and resolution. The 
outcome of positive control (untreated infected) group 
with those of fifth (ointment with oral medicine) group 
were also significantly different (P ≤ 0.045); such that 
local ointment application accompanied by oral medicine 
administration led to the exacerbation of lesion growth 
(Table 2). The Glucantime®-treated and the ointment 
with oral medicine groups also showed a significant dif-
ference (P ≤ 0.039) reflecting that the oil-based ointment 
caused an aggravating effect on lesion size. In contrast, 
oral administration of herbal medicine upon parasite 
inoculation and once ulcer develops did not exhibit any 
significant statistical difference with the Glucantime® 
group (P ≥ 0.05). These oral protocols led to a repair and 
reduction of lesion size.
In the present study, an ulcer developed on average 
about 35 day post-inoculation of amastigote parasites into 
the mice. As indicated in Table 1, the biggest ulcer size 
had a mean area of about 141.86 mm2 due to the local 
application of ointment twice daily with oral medicine 
PUD, so that there was a 5-fold increase in the mean ulcer 
size from the start to the end of this treatment. The largest 
ulcer growth rate was noted in group IV using local oint-
ment twice (A.M. and P.M.) a day PUD without any oral 
administration, such that there was an 8.87-fold increase 
in the mean ulcer size from the start to the end of treat-
ment. On the other hand, the smallest ulcer size with a 
final mean area of about 14.64 mm2 was recorded in that 
group of mice receiving aqueous oral medicine upon par-
asite inoculation. The mean ulcer size from the start to the 
end of this treatment grew by only 1.03-fold. Likewise, the 
mean ulcer size in Glucantime® group grew by 1.6-fold 
which indicated that oral drug administrations have had 
meaningful effects on the prevention of lesion growth due 
to the intracellular proliferation of L. major amastigote 
parasites within tissue macrophages.
Table 1. Average lesion size (mm2) and its growth rate among different treatment 
groups of mice during a five-week period
Groups† / Weeks 1 2 3 4 5 Lesion growth rate
I: –ve. Control - - - - - -
II: +ve. Control 6.76 16.76 20.78 22.84 - 3.37
III: Glucantime PUD* 11.07 18.38 17.82 - - 1.60
IV: Oint. PUD 10.17 44.44 59.19 90.23 - 8.87
V: Oint./Oral PUD 28.16 68.84 81.74 141.86 - 5.03
VI: Oral on Inject. 10.14 8.75 8.24 10.92 14.64 1.44
VII: Oral on Ulcer 12.80 16.99 22.93 29.68 29.23 2.28
VIII: Oint.-base crème 12.90 19.59 42.02 47.67 - 3.69
†Numbers I-VIII refer to different treatment protocols, *PUD = post ulcer development.
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Table 2. Statistical analyses from multiple comparisons of oral and local wormwood extract 
administrations under in vivo conditions on BALB/c mice using pair wise Dunnett’s T3 test to 
determine the significant differences between different variables. 
Variable† (I) Variable† (J) Mean difference 
(I-J)
Standard error Significance level 95% Confidence interval   





























































































































































































































































†Numbers II-VIII refer to different treatment protocols, *The mean difference is significant at the 0.05 level.
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4. Discussion
Cutaneous leishmaniasis mostly caused by the intracel-
lular Leishmania major amastigote parasites remains 
a formidable therapeutic challenge and a serious pub-
lic health concern in most tropical countries, including 
Iran2,3, though occasionally other infectious and non-
infectious diseases could also be superimposed13,18,29. 
Although the pentavalent antimony compounds such as 
sodium stibogluconate (Pentostam®; Glaxco Wellcome, 
UK) and meglumine antimoniate (Glucantime®; Aventis, 
France) are the first-line drugs used in the treatment of all 
forms of leishmaniases, the report of cases of resistance 
to these drugs and the fact that they have to be admin-
istered parenterally represent the main hurdles for the 
chemotherapy of leishmaniases11. Unfortunately, no ideal 
treatments for the leishmaniases have yet been advo-
cated9.
There appears to be a new herbalism trend in search 
of folk medicines to treat human infectious diseases with 
increasing frequency41. Novel approaches including the 
oral administration of natural pharmaceutical products 
from medicinal herbs such as wormwood, Artemisia, have 
been proposed33. The currently well-known anti-malaria 
compound, artemisinin (a sesquiterpene with an endo-
peroxide bridge), is derived from this plant24,36. In the in 
vivo test, this compound in micromolar concentrations 
has been reported to reduce the severity of lesions caused 
by Leishmania amazonensis in BALB/c mice14. The toxic-
ity of artemisinin derivatives for laboratory animals and 
its safe use in man have also been reviewed15. The rapid 
reduction of parasitaemia and short elimination half-life 
(with an almost immediate effect) of these compounds 
after oral administration are elucidated in this review. 
The toxicity resulting from the oil-based formulations is 
also implicated, which is compatible with the data from 
the present study. Orally administered chemotherapeu-
tic agents (e.g., as salt) have the privilege of minimizing 
socioeconomic problems associated with populations liv-
ing in endemic areas where the infrastructure of health 
care facilities is rudimentary30.
The leaf and seed extracts of the annual or sweet 
wormwood, Artemisia annua, have been shown to medi-
ate apoptosis in Leishmania donovani, the cause of visceral 
leishmaniasis (Kala-azar) in the Indian subcontinent19. 
Furthermore, the in vivo studies have indicated that a 
70% ethanol extract from the commonly used vegetable, 
known in Iran as Tarkhoon (Aretmisia dracunculus), had 
potent anti-inflammatory (or antiulcer) activity32. Other 
studies have confirmed that the leaves from this medici-
nal herb have inhibitory effects on blood platelet adhesion 
and aggregation in rats37. This could mean swift flow of 
blood from the site of lesion and carriage of Leishmania-
infected macrophages to remote vessels where they can 
readily be cleared by the host’s immune responses.
The main aim of using an animal model such as mice 
is to deplore a drug that can be administered orally, be 
effective in a short period (<10 days) and have minimal 
sign of side-effects at the highest testable doses (100 mg/
kg). According to recent reports10,26, the BALB/c mouse 
– L. major model has extensively been used in drug dis-
covery studies but it is an exceptionally rigorous non-cure 
model in which the most active drugs have any efficacy 
and absolute cure is scarce. The treatment of CL is difficult 
due to the intracellular (within macrophages) location 
and replication of the infectious Leishmania amastigote 
parasites. The main observation from the present study 
was that oral in vivo treatment with an aqueous extract 
of A. absinthium was found to be effective in experi-
mental murine models of CL. As oral administration of 
this herbal extract provided a prolonged slow release of 
active ingredients in mice which probably potentiated the 
host immune responses, the lesion growth rate was thus 
minimized with this route of administration compared 
with other choices. In contrast, the dermal application 
of an ointment-based crème formulation culminated in 
increased lesion growth rate indicating that the oil-based 
moiety prevented lesion resolution. This finding was in 
accordance with other studies15. The present finding, that 
oral herbal extract administration was also slightly more 
effective than Glucantime® i.m. use, was supported by the 
data reported from another similar in vivo model system 
using Artemisia auchery38.
One of the main limitations of this study was that the 
determination of drug efficacy by scoring 3-dimensional 
changes in lesion size during and after the course of treat-
ment could be biased as much of the lesion consists of 
inflammatory cells such as macrophages filled with amas-
tigotes limited to the dermal layer of the skin. Culturing 
parasites from skin biopsies gives an alternative quantita-
tive score of activity10. This was accomplished in a recent 
publication4.
The lack of a suitable association between the data 
acquired by the in vitro bioassays and those from the in 
vivo evaluations, as well as the necessity to have rapid and 
simple evaluation procedures in which all species and 
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strains of Leishmania could be incorporated, have stimu-
lated the search for novel bioassay techniques to confirm 
leishmanicidal activity7. This is exemplified by the follow 
up and uptake by parasites of radioactive trace elements 
such as the use of tritiated hydrogen [3H] atom in medici-
nal herbs.
It was thus concluded from the present data that oral 
administration of A. absinthium herbal extract due to its 
pharmaceutical chemical entities had the most thera-
peutic effect on lesions due to the L. major amastigote 
parasites in susceptible BALB/c mice. It seems that A. 
absinthium extract as an oral feeder caused modulation 
of host responses, ulcer size reduction and tissue repair. 
In contrast, ointment formulation from this extract had 
an inverse effect on ulcer size and its diameter increased 
possibly due to its impregnation with an oil moiety.
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